For COPD patients the PBS is to remove the clinical criteria restricting access to patients with a FEV1 <50% of predicted for triple therapy Trelegy (fluticasone furoate with umeclidinium and vilanterol) from 1 March 2020. The move is expected to allow more than 16,000 patients per year to access triple therapy. It follows a recommendation ...
PBS broadens access to COPD triple therapy and lung cancer immunotherapy
By Michael Woodhead
20 Feb 2020